Pathology associated with sporadic Parkinson’s disease — where does it end?

  • H. Braak
  • C. M. Müller
  • U. Rüb
  • H. Ackermann
  • H. Bratzke
  • R. A. I. de Vos
  • K. Del Tredici
Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 70)

Summary

Parkinson’s disease (PD) is a multisystem disorder in which predisposed neuronal types in specific regions of the human peripheral, enteric, and central nervous systems become progressively involved. A staging procedure for the PD-related inclusion body pathology (i.e., Lewy neurites and Lewy bodies) in the brain proposes that the pathological process begins at two sites and progresses in a topographically predictable sequence in 6 stages. During stages 1–2, the inclusion body pathology remains confined to the medulla oblongata, pontine tegmentum, and anterior olfactory structures. In stages 3–4, the basal mid- and forebrain become the focus of the pathology and the illness reaches its symptomatic phase. In the final stages 5–6, the pathological process is seen in the association areas and primary fields of the neocortex. To date, we have staged a total of 301 autopsy cases, including 106 cases with incidental pathology and 176 clinically diagnosed PD cases. In addition, 163 age-matched controls were examined. 19 of the 301 cases with PD-related pathology displayed a pathological distribution pattern of Lewy neurites and Lewy bodies that diverged from the staging scheme described above. In these cases, olfactory structures and the amygdala were predominantly involved in the virtual absence of brain stem pathology. Most of the divergent cases (17/19) had advanced concomitant Alzheimer’s disease-related neurofibrillary changes (stages IV-VI).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbott RD, Petrovitch H, White LR et al. (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57: 456–462PubMedGoogle Scholar
  2. Ahlskog JE (2005) Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord 20: 271–282PubMedCrossRefGoogle Scholar
  3. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59: 102–112PubMedCrossRefGoogle Scholar
  4. Arai A, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888: 287–296PubMedCrossRefGoogle Scholar
  5. Braak H (1980) Architectonics of the human telencephalic cortex. Springer, Berlin Heidelberg, pp 1–147Google Scholar
  6. Braak H, Braak E (1992) The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 15: 6–31PubMedCrossRefGoogle Scholar
  7. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88:493–500PubMedGoogle Scholar
  8. Braak H, Braak E, Yilmazer D, Schultz C, Bohl J (1995) Age-related changes of the human cerebral cortex. In: Cruz-Sanchez FF, Ravid R, Cuzner ML (eds) Neuropathological diagnostic criteria for brain banking. IOS Press, Amsterdam, pp 14–19 (Biomedical Health Research, vol 10)Google Scholar
  9. Braak H, Del Tredici K (2004) Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 25:19–23PubMedCrossRefGoogle Scholar
  10. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003a) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197–211PubMedCrossRefGoogle Scholar
  11. Braak H, Rüb U, Del Tredici K (2003b) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517–536PubMedCrossRefGoogle Scholar
  12. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318: 121–134PubMedCrossRefGoogle Scholar
  13. Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, de Vos RAI (2005) Cognitive status correlates with neuropathological stage in Parkinson disease. Neurology 64: 1404–1410PubMedGoogle Scholar
  14. Brooks DJ (2000) Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease. J Neurol 247[Suppl 2]:11–18Google Scholar
  15. Del Tredici K, Braak H (2004) Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy. In: Kahle P, Haass C (eds) Molecular mechanisms in Parkinson’s disease. Landes Bioscience, Georgetown, TX, pp 1–32Google Scholar
  16. Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426PubMedGoogle Scholar
  17. Dickson DW (1998) Aging in the central nervous system. In: Markesbery WR (ed) Neuropathology of dementing disorders. Arnold, London New York, pp 56–88Google Scholar
  18. Doty RL (2001) Olfaction. Ann Rev Psych 52:423–452CrossRefGoogle Scholar
  19. Forno LS (1969) Concentric hyaline intraneuronal inclusions of Lewy body type in the brain of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 17: 557–575PubMedGoogle Scholar
  20. Galvin JE, Lee VMY, Trojanowski JQ (2001) Synucleinopathies. Clinical and pathological implications. Arch Neurol 58: 186–190PubMedCrossRefGoogle Scholar
  21. Geddes JW (2005) α-Synuclein: a potent inducer of tau pathology. Exp Neurol 192: 244–250PubMedCrossRefGoogle Scholar
  22. Goedert M (2001) The significance of tau and α-synuclein inclusions in neurodegenerative diseases. Curr Opin Genet Dev 11: 343–351PubMedCrossRefGoogle Scholar
  23. Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10: 378–384PubMedCrossRefGoogle Scholar
  24. Hawkes CH (2003) Olfaction in neurodegenerative disorder. Mov Disord 18: 364–372PubMedCrossRefGoogle Scholar
  25. Hawkes CH, Shephard BC, Daniel SE (1999) Is Parkinson’s disease a primary olfactory disorder? Q J Med 92: 473–480Google Scholar
  26. Hopkins DA, Bieger D, de Vente J, Steinbusch HWM (1996) Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Progr Brain Res 107: 79–96Google Scholar
  27. Huang XF, Törk I, Paxinos G (1993) Dorsal motor nucleus of the vagus nerve: a cyto-and chemoarch-itectonic study in the human. J Comp Neurol 330:158–182PubMedCrossRefGoogle Scholar
  28. Jellinger KA (2003a) Neuropathological spectrum of synucleinopathies. Mov Disord 18[Suppl 6]:2–12CrossRefGoogle Scholar
  29. Jellinger KA (2003b) Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution — a pilot study. Acta Neuropathol 106: 191–201PubMedCrossRefGoogle Scholar
  30. Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111: 1219–1235PubMedCrossRefGoogle Scholar
  31. Jellinger KA, Mizuno Y (2003) Parkinson’s disease. In: Dickson DW (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 159–187Google Scholar
  32. Koller WC, Langston JW, Hubble JP et al. (1991) Does a long preclinical period occur in Parkinson’s disease? Neurology 41[Suppl 2]: 8–13PubMedGoogle Scholar
  33. Kotzbauer PT, Trojanowski JQ, Lee VMY (2001) Lewy body pathology in Alzheimer’s disease. J Mol Neurosci 17: 225–232PubMedCrossRefGoogle Scholar
  34. Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62: 1241–1253PubMedGoogle Scholar
  35. Lang AE, Obeso JA (2004) Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 3: 309–316PubMedCrossRefGoogle Scholar
  36. Lantos PL, Quinn N (2003) Multiple sytem atrophy. In: Dickson DW (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 203–214Google Scholar
  37. Lowe J (1994) Lewy bodies. In: Calne DP (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 51–69Google Scholar
  38. Mesholam RL, Moberg PJ, Mahr RN, Doty RL (1998) Olfaction in neurodegenerative disease. A meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol 55: 84–90PubMedCrossRefGoogle Scholar
  39. Mikolaenko I, Pletnikova O, Kawas CH et al. (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64: 156–162PubMedGoogle Scholar
  40. Morrish PK, Rakashi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with (18F)dopa PET. J Neurol Neurosurg Psychiatry 64: 314–319PubMedCrossRefGoogle Scholar
  41. Neumann M, Müller V, Kretschmar HA, Haass C, Kahle PJ (2004) Regional distribution of proteinase-K a-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 63: 1225–1235PubMedGoogle Scholar
  42. Pankratz N, Foroud T (2004) Genetics of Parkinson disease. Neurotox 2: 235–242Google Scholar
  43. Parkinnen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57: 82–91CrossRefGoogle Scholar
  44. Pearce RK, Hawkes CH, Daniel SE (1995) The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10: 283–287PubMedCrossRefGoogle Scholar
  45. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56: 173–181PubMedCrossRefGoogle Scholar
  46. Rachakonda V, Pan TH, Le WD (2004) Biomarkers of neurodegenerative disorders: how good are they? Cell Res 14: 349–360CrossRefGoogle Scholar
  47. Saito Y, Kawashima A, Ruberu NN et al. (2003) Accumulation of phosphorylated α-synuclein in aging human brain. J Neuropathol Exp Neurol 62: 644–654PubMedGoogle Scholar
  48. Saito Y, Ruberu NN, Sawabe M et al. (2004) Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63: 742–749PubMedGoogle Scholar
  49. Sawle GV (1993) The detection of preclinical Parkinson’s disease: what is the role of positron emission tomography? Mov Disord 8: 271–277PubMedCrossRefGoogle Scholar
  50. Stiasny-Kolster K, Doerr Y, Möller JC et al. (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137PubMedCrossRefGoogle Scholar
  51. Takahashi H, Wakabayashi K (2001) The cellular pathology of Parkinson’s disease. Neuropathology 21: 315–322PubMedCrossRefGoogle Scholar
  52. Takahashi H, Wakabayashi K (2005) Controversy: is Parkinson’s disease a single disease entity? Yes. Parkinsonism Rel Disord 11: 31–37CrossRefGoogle Scholar
  53. Thal DR, Del Tredici K, Braak H (2004) Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 23: 1–13Google Scholar
  54. Tissingh G, Berendse HW, Bergmans P et al. (2001) Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 16: 41–46PubMedCrossRefGoogle Scholar
  55. Wakabayashi K, Takahashi H, Ohama E, Ikuta F (1990) Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79: 581–583PubMedCrossRefGoogle Scholar
  56. Wolters EC, Francot C, Bergmans P, Winogrodzka A, Booij J, Berendse HW, Stoof JC (2000) Preclinical (premotor) Parkinson’s disease. J Neurol 247[Suppl 2]: 103–109Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • H. Braak
    • 1
  • C. M. Müller
    • 1
  • U. Rüb
    • 1
  • H. Ackermann
    • 2
  • H. Bratzke
    • 3
  • R. A. I. de Vos
    • 4
  • K. Del Tredici
    • 1
  1. 1.Institute for Clinical NeuroanatomyJ.W. Goethe UniversityFrankfurt/MainGermany
  2. 2.Department of BiomathematicsJ.W. Goethe UniversityFrankfurt/MainGermany
  3. 3.Institute for Forensic MedicineJ.W. Goethe UniversityFrankfurt/MainGermany
  4. 4.Laboratorium Pathologie Oost NederlandEnschedeThe Netherlands

Personalised recommendations